
Roy Ξ
@roy_ehling
Protein Engineering - Immunotechnology. Small biotech (He/Him). Opinions are my own.
ID: 300546545
17-05-2011 23:20:23
119 Tweet
114 Followers
231 Following


Joseph Taft LSSI Reddy We also found structural evidence that higher-order network effects between the Omicron mutated sites may perturb the physical and chemical properties of the epitope surface for this mAb. biorxiv.org/content/10.110…


Highlighting our recent work from LSSI Reddy involving the construction of combinatorial RBD libraries that were used to infer and validate ACE2 binding and escape from clinically relevant mAbs. Moving towards in silico prediction of escape for emerging variants🤓







Proud to share our *finally* accepted paper. It was a wild ride, but we finally got there on my last day at D-BSSE, ETH Zurich ETH Zürich. Couldn't ask for a better way to finish my time in the LSSI Reddy. cell.com/cell/fulltext/…


Sone good news about the BA.2.75 variant, in case it gets legs: it's not more immune evasive than BA.5, has cross-immunity w/ BA.1/2, and is still sensitive to Evusheld and Bebtelovimab thelancet.com/journals/lanin… The Lancet Infectious Diseases Ben Murrell Tom Peacock Daniel Sheward & colleagues


Happy to share our recent manuscript from LSSI Reddy has been published in Cell! Great work by Joseph Taft & Cédric R Weber et al. Moving towards predicting immune escape of future viral variants🤓



ETH-Zürich (ETH Zurich) has put out a great summary of our DML technique and how it can help us develop more effective antibody therapies and vaccines against future variants of SARS-CoV-2. Read more about it here: ethz.ch/en/news-and-ev…

Here's the preprint by Ben Murrell and colleagues now posted, summarized in his thread biorxiv.org/content/10.110… "BA.2.75.2 was neutralised...five-fold less potently than BA.5... These data raise concerns that BA.2.75.2 may effectively evade humoral immunity in the population."


Excited to share my first last Author paper. Out now in Genome Biology We Buchholz Lab report two new methods. To evolve CRISPR-Cas systems (CaSLiDE) and to screen thousands of variants at once (DEQSeq) Thanks to the amazing team of co-authors! genomebiology.biomedcentral.com/articles/10.11…
